(PharmaNewsWire.Com, February 14, 2019 ) Asia-Pacific Conjugate Vaccine Market:Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. Asia Pacific is the fastest growing market for conjugate vaccines. The conjugate vaccines market in Asia-Pacific is expected to expand at a CAGR of 23.5%, leading to a revenue of USD 66.61 Bn by 2023. By volume, it is anticipated to reach 6,883.55 Million units by 2023, expanding at a CAGR of 21.87%.
A penetration rate of around 95% of DTP conjugate vaccines indicates an excellent coverage in Asia-Pacific countries and very little is left to achieve full penetration for the vaccines. Countries with high populations such as China and India, serve as major target areas for such vaccines, and the introduction of these vaccines would ensure a disease-free society.
Research Report Hub offers wide-ranging collection of market research reports under virtually every market verticals and sub-categories from different publishers across the globe. We offer reliable market intelligence reports and report customization services to better understand current and projected market scenarios. It also gives a clearer depiction of industries and facilitates to simply perceive competitor activity in the respective industry. Our services are also geared towards helping organizations procure market reports at the finest price.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: